|
1
|
van Leeuwaarde RS, Ahmad S, van
Nesselrooij B, Zandee W and Giles RH: Von Hippel-Lindau syndrome.
In: GeneReviews®. Adam MP, Feldman J and Mirzaa GM
(eds). University of Washington, Seattle, WA, 2025.
|
|
2
|
Gläsker S, Neumann HPH, Koch CA, Vortmeyer
A, Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A and
Chrousos G (eds): Endotext, Von Hippel-Lindau Disease. MDText.com, South Dartmouth, MA, 2018.
|
|
3
|
Hudler P and Urbancic M: The role of VHL
in the development of von Hippel-Lindau disease and erythrocytosis.
Genes (Basel). 13(362)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Harbi E and Aschner M: Von Hippel-Lindau
syndrome: Clinical features, genetic foundations, and management
strategies. Mol Biol Rep. 52(281)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ohh M, Taber CC, Ferens FG and Tarade D:
Hypoxia-inducible factor underlies von Hippel-Lindau disease
stigmata. Elife. 11(e80774)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Florence JM, Pandya S, King WM, Robison
JD, Baty J, Miller JP, Schierbecker J and Signore LC: Intrarater
reliability of manual muscle test (medical research council scale)
grades in Duchenne's muscular dystrophy. Phys Ther. 72:115–126.
1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hofman FM and Taylor CR:
Immunohistochemistry. Curr Protoc Immunol. 103:21.4.1–21.4.26.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hao Z, Wang Y, Li J, Liu W, Zhao W and
Wang J: Expression of HIF-1α/PKM2 axis correlates to biological and
clinical significance in papillary thyroid carcinoma. Medicine
(Baltimore). 102(e33232)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wong M, Chu YH, Tan HL, Bessho H, Ngeow J,
Tang T and Tan MH: Clinical and molecular characteristics of East
Asian patients with von Hippel-Lindau syndrome. Chin J Cancer.
35(79)2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nielsen SM, Rhodes L, Blanco I, Chung WK,
Eng C, Maher ER, Richard S and Giles RH: Von Hippel-Lindau disease:
Genetics and role of genetic counseling in a multiple neoplasia
syndrome. J Clin Oncol. 34:2172–2181. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Stolle C, Glenn G, Zbar B, Humphrey JS,
Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R and
Linehan WM: Improved detection of germline mutations in the von
Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 12:417–423.
1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maher ER, Nrumann HP and Richard S: von
Hippel-Lindau disease: A clinical and scientific review. Eur J Hum
Gene. 19:617–623. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nordstrom-O'Brien M, van der Luijt RB, van
Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van
Brussel A, Voest EE and Giles RH: Genetic analysis of von
Hippel-Lindau disease. Hum Mutat. 31:521–537. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Crespigio J, Berbel LCL, Dias MA, Berbel
RF, Pereira SS, Pignatelli D and Mazzuco TL: Von Hippel-Lindau
disease: A single gene, several hereditary tumors. J Endocrinol
Invest. 41:21–31. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Weil RJ, Lonser RR, DeVroom HL, Wanebo JE
and Oldfield EH: Surgical management of brainstem hemangioblastomas
in patients with von Hippel-Lindau disease. J Neurosurg. 98:95–105.
2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Panayi C, Antoun N and Sandford R: Bulbar
dysfunction and aspiration pneumonia due to a brainstem
haemangioblastoma: An unusual complication of von Hippel-Lindau
disease. BMJ Case Rep. 13(2016:bcr2016217076)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ammerman JM, Lonser RR, Dambrosia J,
Butman JA and Oldfield EH: Long-term natural history of
hemangioblastomas in patients with von Hippel-Lindau disease:
Implications for treatment. J Neurosurg. 105:248–255.
2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aronow ME, Wiley HE, Gaudric A, Krivosic
V, Gorin MB, Shields CL, Shields JA, Jonasch EW, Singh AD and Chew
EY: Von Hippel-Lindau disease: Update on pathogenesis and systemic
aspects. Retina. 39:2243–2253. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gläsker S: Central nervous system
manifestations in VHL: Genetics, pathology and clinical phenotypic
features. Fam Cancer. 4:37–42. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ong KR, Woodward ER, Killick P, Lim C,
Macdonald F and Maher ER: Genotype-phenotype correlations in von
Hippel-Lindau disease. Hum Mutat. 28:143–149. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang JY, Peng SH, Ning XH, Li T, Liu SJ,
Liu JY, Hong BA, Qi NN, Peng X, Zhou BW, et al: Shorter telomere
length increases age-related tumor risks in von Hippel-Lindau
disease patients. CaIlcer Med. 6:2131–2141. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chang JH, Spraul CW, Lynn ML, Drack A and
Grossniklaus HE: The two-stage mutation model in retinal
hemangioblastoma. Ophthalmic Genet. 19:123–130. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tsang SH and Sharma T: Von Hippel-Lindau
disease. Adv Exp Med Biol. 1085:201–203. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hajjaj A, van Overdam KA, Gishti O, Ramdas
WD and Kiliç E: Efficacy and safety of current treatment options
for peripheral retinal haemangioblastomas: A systematic review.
Acta Ophthalmol. 100:e38–e46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Papastefanou VP, Pilli S, Stinghe A,
Lotery AJ and Cohen VML: Photodynamic therapy for retinal capillary
hemangioma. Eye (Lond). 27:438–442. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gao HL, Jin KZ, Wang XH, Chen ZY, Lu RQ,
Huang D and Yu XR: Clinicopathological conference: Multiple
pancreatic cysts with intermittent abdominal discomfort. Fudan Univ
J Med Sci. 44:528–531. 2017.(In Chinese).
|
|
27
|
Laks S, van Leeuwaarde R, Patel D, Keutgen
XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB and
Tirosh A: Pancreatic Manifestations Recommendations Development
Subcommittee of the VHL Alliance. Management recommendations for
pancreatic manifestations of von Hippel-Lindau disease. Cancer.
128:435–446. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Keutgen XM, Hammel P, Choyke PL, Libutti
SK, Jonasch E and Kebebew E: Evaluation and management of
pancreatic lesions in patients with von Hippel-Lindau disease. Nat
Rev Clin Oncol. 13:537–549. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zwolak A, Świrska J, Tywanek E, Dudzińska
M, Tarach JS and Matyjaszek-Matuszek B: Pancreatic neuroendocrine
tumours in patients with von Hippel-Lindau disease. Endokrynol Pol.
71:256–259. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chittiboina P and Lonster RR: Von
Hippel-Lindau disease. Handb Clin Neurol. 132:139–156.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kim E and Zschiedrich S: Renal cell
carcinoma in von Hippel-Lindau disease from tumor genetics to novel
therapeutic strategies. Front Pediatr. 6(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng
Y, Bai C, Zhang Y and Huo L: Diagnostic efficacy of
[68Ga]Ga-NY104 PET/CT to identify clear cell renal cell
carcinoma. Eur J Nucl Med Mol Imaging. 51:4127–4133.
2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Choueiri TK and Kaelin WG Jr: Targeting
the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 26:1519–1530.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Walther MM, Reiter R, Keiser HR, Choyke
PL, Venzon D, Hurley K, Gnarra JR, Reynolds JC, Glenn GM, Zbar B
and Linehan WM: Clinical and genetic characterization of
pheochromocytoma in von Hippel-Lindau families: Comparison with
sporadic pheochromocytoma gives insight into natural history of
pheochromocytoma. J Urol. 162:659–664. 1999.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Aufforth RD, Ramakant P, Sadowski SM,
Mehta A, Trebska-McGowan K, Nilubol N, Pacak K and Kebebew E:
Pheochromocytoma screening initiation and frequency in von
Hippel-Lindau syndrome. J Clin Endocrinol Metab. 100:4498–4504.
2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jonasch E, Donskov F, Iliopoulos O,
Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie
JK, Welsh SJ, et al: Belzutifan for renal cell carcinoma in von
Hippel-Lindau disease. N Engl J Med. 385:2036–2046. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jacob A, Shook J and Hutson TE: Tivozanib,
a highly potent and selective inhibitor of VEGF receptor tyrosine
kinases, for the treatment of metastatic renal cell carcinoma.
Future Oncol. 16:2147–2164. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hrisomalos FN, Maturi RK and Pata V:
Long-term use of intravitreal bevacizumab (avastin) for the
treatment of von hippel-lindau associated retinal
hemangioblastomas. Open Ophthalmol J. 4:66–69. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015.PubMed/NCBI View Article : Google Scholar
|
